GSK to Acquire IDRx in Up-to $1.15 Billion Deal

GSK to Acquire Sierra Oncology for $1.9 Billion

April 13, 2022

Biotechnology

GlaxoSmithKline plc (GSK) has entered into an agreement to acquire late-stage biopharmaceutical company Sierra Oncology, Inc. for $1.9 billion (approximately $55 per share in cash). The acquisition is intended to bring Sierra’s lead asset momelotinib—an investigational targeted therapy for myelofibrosis and anemia—into GSK’s specialty medicines portfolio.

GSK Acquires Elsie Biotechnologies for up to $50M

June 6, 2024

Biotechnology

GSK plc has completed the acquisition of Elsie Biotechnologies, a San Diego–based oligonucleotide-focused biotechnology company, for up to $50 million. The deal integrates Elsie's discovery, synthesis and delivery capabilities into GSK's oligonucleotide R&D platform to accelerate development of therapeutics for chronic hepatitis B, steatotic liver disease and other difficult-to-treat diseases.

GSK to Acquire Aiolos Bio

January 9, 2024

Pharmaceuticals

GSK plc has entered an agreement to acquire Aiolos Bio, a clinical-stage biopharmaceutical company focused on unmet needs in respiratory and inflammatory conditions, for a $1 billion upfront payment and up to $400 million in success-based regulatory milestone payments. The deal gives GSK access to Aiolos’ AIO-001, a long-acting anti-TSLP monoclonal antibody (phase II-ready) intended for adult asthma and potentially additional indications.

GSK Acquires Affinivax, Inc.

August 16, 2022

Biotechnology

GSK plc acquired clinical-stage biopharmaceutical company Affinivax, Inc., paying $2.1 billion upfront and up to $1.2 billion in potential development milestones to gain the MAPS vaccine platform and a 24‑valent pneumococcal vaccine candidate (AFX3772) in development. The acquisition (100% of outstanding shares) expands GSK's vaccines R&D capabilities and pipeline, with AFX3772 in phase II and preparations underway for phase III.

GSK to Acquire BELLUS Health for $2.0 Billion

April 18, 2023

Biotechnology

GSK plc entered into an agreement to acquire BELLUS Health Inc. in a cash deal valued at approximately US$2.0 billion (US$14.75 per share). The acquisition is intended to give GSK access to camlipixant, a late-stage (phase III) highly selective P2X3 antagonist for refractory chronic cough, with anticipated regulatory approval and launch in 2026 and expected EPS accretion from 2027.

Gilead Sciences Acquires Immunomedics

September 13, 2020

Biotechnology

Gilead Sciences agreed to acquire Immunomedics for $88.00 per share in an all-cash transaction valuing Immunomedics at approximately $21 billion. The acquisition gives Gilead global rights (outside certain Asian territories) to Trodelvy, an FDA‑approved antibody‑drug conjugate for metastatic triple‑negative breast cancer, and accelerates Gilead’s expansion into oncology.